GlassScriptPhysician profile
Subhasree Misra
NPI 1326092362
$115,333.77
in general payments reported to CMS, 2019-2025
50 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $21K · 2021: $41K · 2022: $12K · 2023: $49.27 · 2024: $147 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $58,617.92 | 2019-2025 | Vumerity, Tysabri |
| Abbvie INC. | $20,457.12 | 2021-2025 | |
| Allergan, INC. | $9,932.39 | 2019-2021 | |
| Genzyme Corporation | $8,998.10 | 2019-2024 | |
| Neurelis, INC. | $5,708.67 | 2020-2022 | |
| Tg Therapeutics, INC. | $1,452.25 | 2021-2022 | |
| Livanova USA, INC. | $1,359.69 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,282.26 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $923.02 | 2019-2022 | |
| Emd Serono, INC. | $897.41 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $562.86 | 2019-2022 | |
| Mdd US Operations, LLC | $488.20 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $366.46 | 2019-2022 | |
| Eisai INC. | $291.91 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $266.74 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhasree Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.